OPTI vs. HEMO, OBI, OBD, NSCI, DEST, SBTX, ONC, SAR, SNG, and BVX
Should you be buying OptiBiotix Health stock or one of its competitors? The main competitors of OptiBiotix Health include Hemogenyx Pharmaceuticals (HEMO), Ondine Biomedical (OBI), Oxford BioDynamics (OBD), NetScientific (NSCI), Destiny Pharma (DEST), SkinBioTherapeutics (SBTX), Oncimmune (ONC), Sareum (SAR), Synairgen (SNG), and BiVictriX Therapeutics (BVX). These companies are all part of the "biotechnology" industry.
Hemogenyx Pharmaceuticals (LON:HEMO) and OptiBiotix Health (LON:OPTI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, community ranking, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.
Hemogenyx Pharmaceuticals has higher earnings, but lower revenue than OptiBiotix Health. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than OptiBiotix Health, indicating that it is currently the more affordable of the two stocks.
Hemogenyx Pharmaceuticals' return on equity of -85.52% beat OptiBiotix Health's return on equity.
In the previous week, Hemogenyx Pharmaceuticals and Hemogenyx Pharmaceuticals both had 1 articles in the media. OptiBiotix Health's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.
Hemogenyx Pharmaceuticals has a beta of 3.06, indicating that its share price is 206% more volatile than the S&P 500. Comparatively, OptiBiotix Health has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500.
OptiBiotix Health received 90 more outperform votes than Hemogenyx Pharmaceuticals when rated by MarketBeat users. Likewise, 59.18% of users gave OptiBiotix Health an outperform vote while only 57.89% of users gave Hemogenyx Pharmaceuticals an outperform vote.
0.8% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.3% of OptiBiotix Health shares are owned by institutional investors. 11.0% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Comparatively, 13.3% of OptiBiotix Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
OptiBiotix Health beats Hemogenyx Pharmaceuticals on 8 of the 11 factors compared between the two stocks.
Get OptiBiotix Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
OptiBiotix Health Competitors List
Related Companies and Tools